linjc16/ctgov huggingface dataset:
Tongue Pressure Recording During Speech

Study Overview
=================
Brief Summary
-----------------
This research is about tongue's pressure during speech, using a complete denture which allows respecting tongue and speech physiology at the best. A strain gauge transducer is placed inside this prosthodontics device. During speech, the pressure and the sounds are recording. The analysis of the twos signals should explain what pressure is needed for what sound. The comparison between old complete denture wearers and new one is realized to provide informations about tongue adaptation's phenomenon.

Official Title
-----------------
Experimental Study About Tongue Interactions With Teeth and Palate During Speech, Using Strain Gauge Transducer and Complete Denture. Comparison of Adaptation Phenomenon's Between Patients With New Complete Denture.

Conditions
-----------------
Complete Toothless

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: new prosthodontics device or change of prosthodontics device male or female Age upper 18 French as native language Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Speech,, tongue,, pressure,, transducer,, complete denture
Reinforcing Therapist Performance

Study Overview
=================
Brief Summary
-----------------
The specific aims of the proposed study are to evaluate the effectiveness and cost-effectiveness of providing monetary incentives to therapists as a method to improve implementation of evidence-based treatments.

Official Title
-----------------
Reinforcing Therapist Performance

Conditions
-----------------
Substance Use

Intervention / Treatment
-----------------
* Behavioral: Incentive


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must work at one of the participating demonstration sites funded by the Center for Substance Abuse Treatment to deliver the Adolescent Community Reinforcement Approach and/or Assertive Continuing Care.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: Incentive<br> | Behavioral: Incentive<br>* Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Target A-CRA | Based on a review of recordings of actual client sessions is an indicator of whether or not clients received 10 or more of 12 specified treatment procedures within no less than seven treatment sessions. | 14 weeks post intake | 
| A-CRA Competence | Based on review of a randomly selected session recording is an indicator of whether or not participants delivered at least one treatment procedure at or above the level of competence required as part of the certification process. | Monthly | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of days abstinent | Based on client self report is the percentage of days during the past 90 days that clients reported not using any alcohol or other drugs. | 6 months post-intake | 
| Pay-for-performance Cost-Effectiveness | The cost per unit of Target A-CRA, A-CRA Competene, and Percentage of Days Abstient in the experimental condition relative to the control condition. | First six months of study |
OPTIMIZATION of ADVANCED MR SEQUENCES

Study Overview
=================
Brief Summary
-----------------
This monocentric methodological study aims at optimizing advanced MR sequences for image quality (reduced artefacts, signal to noise ratio, acquisition time, stability of quantitative measurements) on a new MR unit dedicated to research in clinical and cognitive neuroscience.

Detailed Description
-----------------
Primary goal : Optimization of MR protocols and validation of acquisition parameters of advanced MR sequences on healthy volunteers or patients on a new 3T MR unit dedicated to research in neurosciences. Secondary goals Perform acquisitions to validate the feasibility of research MR protocols (pilot subjects) reproducibility studies

Official Title
-----------------
OPTIMIZATION of AVANCED MR SEQUENCES for BRAIN STUDIES in VOLUNTEERS (HEALTHY and PATIENTS)

Conditions
-----------------
Neurosciences, MRI, Brain Tumor, Mental Disorders, Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 ans Covered by social security For women in age of procreation, under efficient contraception Written consent Exclusion Criteria: Any MR contraindication Claustrophobia Pregnancy Under judiciary protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MR sequences optimization | Optimization of MR protocols and validation of acquisition parameters of advanced MR sequences on healthy volunteers or patients on a new 3T MR unit dedicated to research in neurosciences. Outcome measures depend on each pulse optimized sequence (signal-to-noise ratio, contrast-to-noise ratio, quantitative MR biomarkers). | 72 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reproducibility studies | Reproducibility studies (quantitative parameters, effect of denoising ...). Outcome measures depend on each pulse optimized sequence (artifacts, signal-to-noise ratio, contrast-to-noise ratio, quantitative MR biomarkers). | 72 months | 
| Pilot studies | Feasibility studies in cognitive neurosciences. Outcome measures depend on each MR protocol (artifacts, signal-to-noise ratio, contrast-to-noise ratio, quantitative MR biomarkers). | 72 months |
Vaccination Status, Knowledge and Attitude in Korean Patients With IBD

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the vaccination status, knowledge about vaccination, and attitude to vaccination of the Korean patients with inflammatory bowel diseases

Detailed Description
-----------------
Using structured questionnaires, the vaccination status, knowledge about vaccination, and attitude to vaccination of the Korean patients with inflammatory bowel diseases will be investigated. The descriptive analyses will be performed and the factors influencing the vaccination status, knowledge, and attitude will be investigated.

Official Title
-----------------
Vaccination Status, Knowledge About Vaccination and Attitude to Vaccination in Korean Patients With Inflammatory Bowel Diseases

Conditions
-----------------
Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Other: Survey with structured questionnaire form for inflammatory bowel disease patient group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Crohn's disease or ulcerative colitis Patients who are visiting Asan Medical Center for the first time for the management of inflammatory bowel diseases Patients who give consent for participating in the study Exclusion Criteria: Patients who refuse to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Inflammatory bowel diseases<br>Patients who have inflammatory bowel diseases and who give consent to participate in the survey | Other: Survey with structured questionnaire form for inflammatory bowel disease patient group<br>* For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccination status (MMR, DTaP, BCG, Polio, seasonal influenza, pneumococcus, HAV, HBV, HPV, VZV, and menigococcus ) | Vaccination status (MMR, DTaP, BCG, Polio, seasonal influenza, pneumococcus, HAV, HBV, HPV, VZV, and menigococcus ) | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge about vaccination in patients with inflammatory bowel diseases | Knowledge about vaccination in patients with inflammatory bowel diseases | One year |
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry

Study Overview
=================
Brief Summary
-----------------
The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating blood (cellsearch) or in marrow hematopoietic (flow cytometry). Pilot study on 180 patients infected by prostate cancer at all stage of disease, show that c-met marker , integrin alpha 2 and 6 expressed in marrow and quantified by flow cytometry were predictor of metastatic progress. In this new study the investigators will analyze antibody panel by cellsearch and flow cytometry on marrow sample of castration-Resistant prostate cancer patients.

Official Title
-----------------
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Biological: Bone marrow sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed adenocarcinoma or prostate Ongoing effective androgen deprivation therapy (testosterone ≤ 50 ng/mL) Castration-Resistant prostate cancer patient : defined as a minimum of 3 rising PSA values assessed and/or radiological progress confirmed by RECIST and PCWG2 Patient who signed informed consent Exclusion Criteria: Severe disorders of coagulation Major skin lesion on iliac crests Allergies in local anesthetics Psychological instability or psychiatric histories Uncertain follow-up and distant residence History of another invasive cancer and hematologic disease Patient deprived of their freedom by court or administrative order Revocation of consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CellSearch<br> | Biological: Bone marrow sampling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk of death according to positive makers |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk of clinical progression according to positive markers. |  | Two years | 
| Risk of biological progression according to positive markers. |  | Two years | 
| Risk of radiological progression according to positive markers. |  | Two years |
Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

Detailed Description
-----------------
The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo. Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated measures.

Official Title
-----------------
Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis, Immune System Diseases

Intervention / Treatment
-----------------
* Drug: ocrelizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who are eligible for Ocrelizumab therapy based on FDA criteria Exclusion Criteria: All patients who are ineligible for Ocrelizumab therapy based on FDA criteria. Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests. Hepatitis B and HIV infections. Pregnant or lactating women. Hypersensitivity to trial medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MS-ocrelizumab treated<br>ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start | Drug: ocrelizumab<br>* FDA-approved MS drugs<br>* Other names: interferon-beta;|
| MS untreated<br>age- and sex-matched untreated MS controls | |
| Healthy control<br>age- and sex-matched untreated healthy controls | |
| MS interferon-treated<br>MS with ongoing interferon-beta therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune subsets, measured through lymphocyte surface marker stains, from patients, before and after ocrelizumab (Ocrevus) therapy | Mononuclear cells (MNC) will be stained, for flow cytometry, with marker antibodies to B cells. The change in the percentage of each subset will be compared before and after treatment with paired T tests and ANOVA. | 1 year |
Intravenous and Topical Analgesics for Procedural Pain in Neonates

Study Overview
=================
Brief Summary
-----------------
This study will test which type of pain medication is best for the management of pain in newborn preterm and full-term infants having a deep intravenous cannula inserted. It will compare the effectiveness of intravenous morphine alone, a local anaesthetic cream (amethocaine) alone, and both medications together. It will also determine the safety of both medications.

Official Title
-----------------
Systemic Analgesia and Local Anaesthesia for Percutaneous Venous Catheter Placement in Preterm Neonates

Conditions
-----------------
Pain, Infant, Newborn

Intervention / Treatment
-----------------
* Drug: morphine, amethocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: preterm and full-term infants in the NICU requiring a percutaneous central venous catheter ventilatory support in the form of conventional ventilation, Continuous Positive Air Pressure (CPAP) or High Frequency Oscillation(HFO) Exclusion Criteria: seizures receiving muscle relaxants skin disorders causing disruption of stratum corneum

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 30 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: morphine, amethocaine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - Facial grimacing, as assessed by brow bulge, at the time of the procedure, compared among groups |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| heart rate at the time of procedure |  |  | 
| oxygen saturation at the time of procedure |  |  | 
| local skin reactions at the time of procedure |  |  | 
| blood pressure for 24 hours post procedure |  |  | 
| ventilatory support for 24 hours post procedure |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, analgesia, morphine, amethocaine, neonate
Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to prove the improvement of pubo-femoral distance by early abduction splintage in one-month-old infants with developmental dysplasia of the hip (with a clinical stable hip but an abnormal hip ultrasonography).

Official Title
-----------------
Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip : Improvement or Overtreatment ?

Conditions
-----------------
Congenital Hip Dysplasia

Intervention / Treatment
-----------------
* Device: Abduction splintage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term infants Infants between 1 and 2 months of age at inclusion Clinically stable hip Pathological ultrasonography : pubo-femoral distance >6mm and bony rim percentage <50% Non objection of the family Exclusion Criteria: Clinically unstable hip Normal ultrasonography Neuro-orthopedic disease Postural deformity of the pelvis Participation refusal

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 2 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A - Abduction splintage<br>Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients. | Device: Abduction splintage<br>* Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.<br>* Other names: Neut Supple Hip Abduction Cushion Without Bone;|
| B - Surveillance<br>No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Normal or abnormal hip ultrasound | A normal or abnormal hip ultrasound will be base on two outcomes : Pubo-femoral distance (ultrasonographic measurement) : distance between the pubic bone and the cartilaginous femoral head, considered as normal if lower than 6mm. Bony rim percentage (ultrasonographic measurement) : percentage of the cartilaginous femoral head covered by the acetabular roof, considered as normal if higher than 50% (or equal to 50%). Data of pubo-femoral distance and bony rim percentage will be pooled to determine if the ultrasound is normal or not for each patient. If one out of two is abnormal, ultrasound is considered abnormal. Statistics will be based on this qualitative value : normal or abnormal ultrasound. | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Abduction splint, Pubo-femoral distance
Patent Foramen Ovale in Children With Migraine Headaches

Study Overview
=================
Brief Summary
-----------------
This study will be the first to provide data about the relationship between PFO and migraine in children. By establishing the actual prevalence, we will better understand if PFO plays a role in the occurence of pediatric migraine and, thus, provide the incentive to perform additional studies evaluating whether PFO closure is an effective treatment option for pediatric migraine. For children with migraine headaches, discovering novel and effective treatments would be life altering.

Detailed Description
-----------------
Specific Aim 1 Using contrast transthoracic echocardiography, compare the prevalence of a PFO in children with migraine headache with the established incidence of PFO published for the general population. Specific Aim 2 Using contrast transcranial Doppler, examine the relationship between the degree of right to left atrial shunting with the presence or absence of aura in children with migraine.

Official Title
-----------------
Patent Foramen Ovale in Children With Migraine Headaches

Conditions
-----------------
Migraine Headaches

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Greater than or equal to six years of age and less than 18 years of age. Diagnosis of migraine headache based on the International Headache Society Criteria. English speaking patients (and parent/guardians where appropriate). Signed informed consent/assent (as appropriate) given by patient, parent or legal guardian. Exclusion Criteria: Inability to cooperate with imaging studies. Known congenital heart disease. Parent or guardian is unwilling to have their child undergo contrast echocardiography.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |
| 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of PFO in children with migraine headaches |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Children, Migraine headaches